Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
The study will comprise of:
A screening period of maximum 28 days
A treatment period of 36 weeks
A follow up period after last dose of study drug
This study will consist of 4 cohorts. Approximately 231 eligible participants will be randomized to AZD6234 or placebo
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults ≥ 18 years of age
BMI of (a) ≥ 30 kg/m2, or (b) ≥ 27kg/m2 and have a current diagnosis of at least 1 weight-related comorbidities (treated or untreated)
A stable body weight for 3 months prior to Screening (±5% body weight change)
You may not be if
Have obesity induced by other endocrine disorders, such as Cushing's syndrome or Prader-Willi syndrome
Has received prescription or non-prescription medication for weight loss within the last 3 months prior to Screening
Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier)
History of type 1 diabetes mellitus or T2DM
Clareo Health | A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity
